Anti-CD318/CDCP1 Antibody (25A11)

Cat. No.: HY-P992209: Data Sheet
FAQs
Technical Support

Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research.

For research use only. We do not sell to patients.

Anti-CD318/CDCP1 Antibody (25A11) Chemical Structure

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Species Reactivity

Human

IC₅₀ & Target^[1]

CDCP1

In Vitro

Anti-CD318/CDCP1 Antibody (25A11) (200 nmol/L) binds to the cell surface of PC-3, DU145, and LNCaP prostate cancer cell lines, confirming CDCP1 protein expression on these cells^[1].
Anti-CD318/CDCP1 Antibody (25A11) (2.5 μg/mL) strongly stains PC-3 prostate cancer cells^[1].
Anti-CD318/CDCP1 Antibody (25A11) (160 nmol/L; 30 min) binds to a distinct epitope of CDCP1 on PC-3 prostate cancer cells, as prebinding of 25A11 Fab does not inhibit CUB1 antibody binding^[1].
Anti-CD318/CDCP1 Antibody (25A11) (0.8 μmol/L; 24 h) potently inhibits PC-3 prostate cancer cell migration (78% inhibition) and invasion (~45% inhibition) in vitro^[1].
Anti-CD318/CDCP1 Antibody (25A11, murine and chimeric forms) and its saporin-conjugate (ch25A11-Sap) (0.001-10 nmol/L; 72 h) are internalized by PC-3 prostate cancer cells, leading to dose-dependent cell killing^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:	PC-3 prostate cancer cell lines
Concentration:	0.8 μM
Incubation Time:	24 h
Result:	Inhibited PC-3 cell migration by 78% and PC-3 cell invasion by ~45%, compared to the PBS/complete medium control. Exhibited migration inhibition superior to the 57% inhibition seen with the positive control 2.5 μmol/L PP2, while the invasion inhibition was comparable to PP2.

Cell Cytotoxicity Assay^[1]

Cell Line:	PC-3 prostate cancer cell lines
Concentration:	0.001-10 nM
Incubation Time:	72 h
Result:	Caused dose-dependent PC-3 cell killing, with cell viability decreasing to ~40-45% at the highest tested concentration of 10 nM.

In Vivo

The anti-CD318/CDCP1 antibody (25A11) saponin custom-directed conjugate (ch25A11-Sap) (0.286-0.4 mg/kg; intravenous injection, subcutaneous injection; days 7-17; 2 subcutaneous injections per week for 3 consecutive weeks after primary tumor resection) shows that intravenously administered ch25A11-saponin conjugate significantly inhibits the growth of PC-3 primary prostate tumors (with a maximum inhibition rate of 67%) and almost completely eliminates lymph node metastases; in contrast, the subcutaneously administered conjugate only inhibits metastases but fails to suppress primary tumor growth; at the tested doses, unconjugated ch25A11 exhibits no activity against either primary tumors or metastases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID CB17 (male/female not specified; injected s.c. with 3×10⁶ PC-3 cells on day 0)^[1]
Dosage:	0.286 mg/kg (ch25A11); 0.4 mg/kg (ch25A11-Sap)
Administration:	i.v. (days 7, 10, 17; ch25A11 followed by twice weekly s.c. for 3 weeks post primary tumor removal); s.c. (days 7, 10, 17; ch25A11-Sap)
Result:	Did not affect PC-3 primary tumor growth compared to PBS control; showed lymph node metastasis incidence of 7/9 on day 46 and 7/9 on day 50, with a mean metastasis size of 225 mm³ on day 46 and 455 mm³ on day 50 (ch25A11 i.v.). Inhibited primary tumor growth by 66% on day 18, 67% on day 22, and 63% on day 23; showed lymph node metastasis incidence of 0/8 on day 46 and 1/8 on day 50, with a mean metastasis size of 0 mm³ on day 46 and <4 mm³ on day 50 (ch25A11-Sap i.v.). Did not inhibit primary tumor growth; showed lymph node metastasis incidence of 0/7 on day 46 and 1/7 on day 50, with a mean metastasis size of 0 mm³ on day 46 and 187 mm³ on day 50 (ch25A11-Sap s.c.).

Gene ID

64866 [NCBI]

Accession

Q9H5V8

Target

CDCP1/CD318

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Siva AC, et al. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res. 2008 May 15;68(10):3759-66.